Related Experiment Video
Updated: Jun 15, 2026
Screening Bioactive Nanoparticles in Phagocytic Immune Cells for Inhibitors of Toll-like Receptor Signaling
Published on: July 26, 2017
Identification of KT-15073 as an inhibitor of lipopolysaccharide-induced microglial activation
Jiyeon Ock1, Su Hyung Hong, Kyoungho Suk
1Department of Pharmacology, School of Medicine, Brain Science and Engineering Institute, CMRI, Kyungpook National University, Daegu,700-412, Korea.
Abstract:
Neuroinflammation has recently been implicated as an important mechanism responsible for the progression of neurodegenerative diseases. Activated microglia produce various proinflammatory cytokines and nitric oxide (NO) that are toxic to neurons. Thus, inhibition of microglial activation may alleviate neuroinflammatory and neurodegenerative processes. Among several fluorovinyloxyacetamide derivatives that were screened by microglia cell-based assay, a novel synthetic compound KT-15073 was identified to strongly attenuate the microglial production of NO and tumor necrosis factor-alpha (TNF-alpha). This compound also suppressed the gene expression of interleukin-1beta, inducible nitric oxide synthase, and TNF-alpha. KT-15073 inhibited the nuclear translocation and DNA binding of nuclear factor-kappaB as well as phosphorylation of p38 mitogen-activated protein kinase. In addition, KT-15073 reduced the cytotoxicity of lipopolysaccharide (LPS)-stimulated microglia toward B35 neuroblastoma cells in the microglia/neuroblastoma coculture, suggesting that the compound might exhibit the neuroprotective activity. Thus, KT-15073 has an anti-inflammatory activity in microglia, and may have a therapeutic potential for the treatment of neuroinflammatory or neurodegenerative diseases.
Insights
A novel compound, KT-15073, effectively reduces neuroinflammation by inhibiting microglial activation and pro-inflammatory cytokine production. This suggests KT-15073 may offer therapeutic potential for neurodegenerative diseases.
Area of Science:
- Neuroscience
- Immunology
- Pharmacology
Background:
- Neuroinflammation, driven by activated microglia, contributes to neurodegenerative disease progression.
- Activated microglia release neurotoxic nitric oxide (NO) and pro-inflammatory cytokines like tumor necrosis factor-alpha (TNF-alpha).
- Inhibiting microglial activation is a potential therapeutic strategy for neuroinflammatory and neurodegenerative disorders.
Purpose of the Study:
- To identify novel compounds that inhibit microglial activation and pro-inflammatory mediator production.
- To evaluate the anti-inflammatory and neuroprotective effects of the identified compound, KT-15073.
Main Methods:
- Screening of fluorovinyloxyacetamide derivatives using a microglia cell-based assay.
- Assessment of nitric oxide (NO) and tumor necrosis factor-alpha (TNF-alpha) production in microglia.
- Analysis of gene expression for interleukin-1beta, inducible nitric oxide synthase, and TNF-alpha.
- Investigation of molecular pathways including nuclear factor-kappaB (NF-kB) and p38 mitogen-activated protein kinase (MAPK).
- Evaluation of neuroprotective effects in a microglia/neuroblastoma co-culture model.
Main Results:
- KT-15073 significantly attenuated microglial production of NO and TNF-alpha.
- The compound suppressed the gene expression of key inflammatory markers: interleukin-1beta, inducible nitric oxide synthase, and TNF-alpha.
- KT-15073 inhibited the nuclear translocation and DNA binding of NF-kB and reduced p38 MAPK phosphorylation.
- KT-15073 demonstrated neuroprotective activity by reducing the cytotoxicity of lipopolysaccharide (LPS)-stimulated microglia towards neuroblastoma cells.
Conclusions:
- KT-15073 exhibits significant anti-inflammatory activity in microglia.
- The compound modulates key inflammatory signaling pathways, including NF-kB and p38 MAPK.
- KT-15073 shows potential therapeutic value for treating neuroinflammatory and neurodegenerative diseases.
